GeoVax Labs has partnered with Leidos on an effort to develop anti-malaria vaccines in support of the United States Agency for International Development. The companies will work to deliver vaccine candidates that combat P. falciparum malaria under USAID's Malaria Vaccine Development Program, GeoVax said Monday.
Leidos and biopharmaceutical company Immunovaccine have expanded a partnership to develop peptide-based vaccines against malaria. The U.S. Agency for International Development and Leidos selected a vaccine delivery formulation based on Immunovaccine’s DepoVax platform for further research and development through a contract extension, Immunovaccine said Tuesday. USAID issued the new contract after the two companies completed various milestones under the Leidos […] More